A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Apalutamide (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms STARTAR
- 31 Aug 2018 Biomarkers information updated
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 23 Jan 2018 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.